Clinical Trial Update: Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating eculizumab for Shiga-toxin related Hemolytic Uremic Syndrome in pediatric patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Uremic Syndrome
• Hemolytic Uremic Syndrome in Childhood

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Hemolytic Uremic Syndrome of Childhood | Phase 3 | Status: COMPLETED